GAMMA Investing LLC Has $225,000 Stock Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

GAMMA Investing LLC increased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 49,082.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,361 shares of the company's stock after acquiring an additional 8,344 shares during the period. GAMMA Investing LLC's holdings in USANA Health Sciences were worth $225,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of USANA Health Sciences by 542.5% during the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after purchasing an additional 971 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in USANA Health Sciences by 635.5% during the 4th quarter. Public Employees Retirement System of Ohio now owns 5,075 shares of the company's stock worth $182,000 after buying an additional 4,385 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in USANA Health Sciences by 83.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,300 shares of the company's stock worth $621,000 after buying an additional 7,877 shares during the period. Millennium Management LLC bought a new stake in USANA Health Sciences during the 4th quarter worth approximately $633,000. Finally, Lazard Asset Management LLC increased its position in USANA Health Sciences by 24,765.5% in the 4th quarter. Lazard Asset Management LLC now owns 7,211 shares of the company's stock valued at $258,000 after acquiring an additional 7,182 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.

Analysts Set New Price Targets

USNA has been the topic of a number of recent research reports. DA Davidson cut their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.

Insider Buying and Selling

In other USANA Health Sciences news, CFO G Doug Iiekking sold 4,548 shares of the stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Walter Noot sold 6,291 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $30.29, for a total value of $190,554.39. The disclosure for this sale can be found here. Insiders sold 12,013 shares of company stock valued at $360,149 over the last quarter. Insiders own 0.63% of the company's stock.

USANA Health Sciences Price Performance

Shares of USANA Health Sciences stock traded up $0.10 during midday trading on Wednesday, reaching $30.81. The company had a trading volume of 137,517 shares, compared to its average volume of 139,187. The stock has a fifty day moving average price of $28.85 and a 200 day moving average price of $30.70. USANA Health Sciences, Inc. has a fifty-two week low of $23.10 and a fifty-two week high of $48.85. The firm has a market cap of $573.68 million, a PE ratio of 16.93, a P/E/G ratio of 0.97 and a beta of 0.63.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.70 by $0.03. USANA Health Sciences had a net margin of 3.98% and a return on equity of 8.94%. The firm had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. During the same quarter in the previous year, the company earned $0.86 EPS. As a group, sell-side analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.